Share Name Share Symbol Market Type Share ISIN Share Description
Genedrive LSE:GDR London Ordinary Share GB00B1VKB244 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 34.50p 32.00p 37.00p 34.50p 34.50p 34.50p 6,250 06:31:56
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 3.1 -6.5 -56.2 - 6.45

Genedrive Share Discussion Threads

Showing 26 to 42 of 50 messages
Chat Pages: 2  1
DateSubjectAuthorDiscuss
05/7/2017
11:14
See previous
the ghost who walks
11/4/2017
07:34
Previous posts
the ghost who walks
30/3/2017
09:21
News. Following closely. See previous
the ghost who walks
27/3/2017
11:17
More news today. Monitoring this closely. R@d
the ghost who walks
17/3/2017
07:59
Previous posts
the ghost who walks
12/3/2017
19:16
See previois
the ghost who walks
11/3/2017
19:45
Yes, something positive. I've been trying to work out how big the HepC opportunity could be. Certainly a worthwhile addition to stable of clinical assets, it's just not going to be a game changer for the company. I have made clear my thoughts about the lack of ability with their R&D function. Nothing more to add sorry.
azzi
11/3/2017
19:45
Yes, something positive. I've been trying to work out how big the HepC opportunity could be. Certainly a worthwhile addition to stable of clinical assets, it's just not going to be a game changer for the company. I have made clear my thoughts about the lack of ability with their R&D function. Nothing more to add sorry.
azzi
17/2/2017
21:02
Looks like my contact was spot on re Epistems resistance to design changes. Sounds like there have been a few over inflated egos influencing the business. I thought the new CEO would have seen through them? Only chance of survival is a massive strategy shift!
azzi
17/2/2017
21:02
Looks like my contact was spot on re Epistems resistance to design changes. Sounds like there have been a few over inflated egos influencing the business. I thought the new CEO would have seen through them? Only chance of survival is a massive strategy shift!
azzi
31/1/2017
19:20
Had it confirmed again that Epistem were working with a world Leading company who strongly advised that they made design changes and improved the sample preparation and cartridge handling protocols. I understand Epistem turned down their recommendations. It appears these are the issues hitting the flagship Tb assay, and preventing its take up in India.
azzi
30/1/2017
18:46
See earlier post on gdr
the ghost who walks
27/1/2017
17:39
See previous poste
the ghost who walks
22/11/2016
09:44
To be clear, I am not a big investor in AIM stocks, Epistem/GDR is my only one, into which I was enticed several years ago. I sold at a loss last year but retain the company on my watch list. Cepheids system is not ldentical to GDR, however they are blessed with a dynamic development team and have many peer reviewed publications out there, yet they are still not breaking into the Indian market Last week I had a day in the Madica conference in Germsny which supports the clinical manufCturing and diagnostic companies. All I could find out about GDR is that they are ploughing ahead with the technology as it stands, though the one delegate who knew the company claimed that they had been working with a big multi national who advised them to make changes to their design and work flow a few years ago. These recommendations were turned down by the old CEO and scientific director apparently. I couldn't find out any more as I had other fish to fry!
azzi
21/11/2016
21:50
Very interesting comment about the Indian political system, I hadn't considered that angle, it can be a tough place to do business. Even the established leader in this TB Dx space, Cepheid, have faced a mountain of difficulties, all of which Genedrive needs to overcome: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967565/ Furthermore, these innovative TB diagnostic platforms have not helped patients at all- there has been no improvement in patient outcome despite these technological offerings. The doctors out in the field are hugely experienced and are not stupid- if it looks like you've got TB then you'll be treated like you've got TB. They dont and wont wait for a GeneXpert or Genedrive to tell them what to do. Cepheid were acquired recently (hxxp://investors.danaher.com/2016-09-06-Danaher-To-Acquire-Cepheid-For-53-00-Per-Share-Or-Approximately-4-Billion) and cintinue to deveop and release next-generation instruments which compete directly with Genedrive
briansewell
21/11/2016
10:28
Thanks Brian for your informative post. Admit, I had to teach myself about isothermal DNA amplification, to simplify, it is a way of amplifying DNA without the need for significant heating and cooling steps required for PCR which is the technology on which Genedrive is based. I have no idea if this company are modifying their platform to run isothermal assays. Remember this would need development of isothermal assays also, frankly Epistem appear transfixed with what they have, hence my critical comments about their R&D, I don't think they have the in house capability to progress, and have to agree that they are being left behind. If I were the CEO, I would be seriously looking to either contract out, or partner with a respected R&D outfit. They have little time left so need to make a move now. I have also been critical of their belief that the Indian political system will accept a system that potentially threatens Indian jobs.....it's a long story.
azzi
18/11/2016
13:16
From what I could find out, the IL28 assay is not a big potential seller at all. I thought the assay was already validated, I guess this news is confirmation? Only significant take up of the Tb assay in India will move the share price All other applications appear to have limited commercial potential.
azzi
Chat Pages: 2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20170824 04:41:42